Thymoglobuline plus basiliximab a mixed cocktail to start?

Jacopo Romagnoli, Franco Citterio, Gionata Spagnoletti, Maria Paola Salerno, Rosaria Calia

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

Recent results reported by Ciancio et al. have demonstrated the long term successful use of dual induction therapy in kidney transplant recipients. Our experience using an “induction cocktail”, thymoglobuline plus basiliximab, started in 2007 and we have treated 235 patients through the past 10 years. In our population, we used a combination of CNIs and MMF or mTORi as maintenance therapy. Our results in term of patient and graft survival, acute rejection rate, renal function and incidence of post-transplant lymphoproliferative disorder support the data reported by Ciancio. We believe that double induction therapy allows on one hand to delay the CNIs introduction, reducing delayed graft function, and on the other hand protects the patient while building the targeted drugs exposures, so reducing the incidence of acute rejection.
Lingua originaleEnglish
pagine (da-a)1-2
Numero di pagine2
RivistaTransplant Immunology
Volume43-44
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Antibodies, Monoclonal
  • Antilymphocyte Serum
  • Basiliximab
  • Drug Therapy, Combination
  • Graft Rejection
  • Graft Survival
  • Graft survival
  • Humans
  • Immunology
  • Immunology and Allergy
  • Induction Chemotherapy
  • Induction therapy
  • Kidney Transplantation
  • Lymphoproliferative Disorders
  • Patient survival
  • Rabbit antithymocyte globulin
  • Recombinant Fusion Proteins
  • Renal transplantation
  • Transplantation

Fingerprint Entra nei temi di ricerca di 'Thymoglobuline plus basiliximab a mixed cocktail to start?'. Insieme formano una fingerprint unica.

Cita questo